NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis

Rheumatoid arthritis (RA) is a progressive autoimmune disease characterized by synovial membrane hyperplasia, inflammation, and angiogenesis. Hepatocyte growth factor (HGF) and its receptor, c-Met, are both overexpressed in the RA synovium. NK4 is an antagonist of HGF which has been shown to inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabquer, Bradley J, Koch, Alisa E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979028/
https://www.ncbi.nlm.nih.gov/pubmed/24074223
http://dx.doi.org/10.1186/ar4320
_version_ 1782310672645750784
author Rabquer, Bradley J
Koch, Alisa E
author_facet Rabquer, Bradley J
Koch, Alisa E
author_sort Rabquer, Bradley J
collection PubMed
description Rheumatoid arthritis (RA) is a progressive autoimmune disease characterized by synovial membrane hyperplasia, inflammation, and angiogenesis. Hepatocyte growth factor (HGF) and its receptor, c-Met, are both overexpressed in the RA synovium. NK4 is an antagonist of HGF which has been shown to inhibit tumor growth, metastasis, and angiogenesis. In an experimental model of RA, NK4 gene therapy inhibited joint damage and inflammation in both preventative and therapeutic models. NK4 treatment therefore represents a possible therapeutic option in combating RA.
format Online
Article
Text
id pubmed-3979028
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39790282014-04-09 NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis Rabquer, Bradley J Koch, Alisa E Arthritis Res Ther Editorial Rheumatoid arthritis (RA) is a progressive autoimmune disease characterized by synovial membrane hyperplasia, inflammation, and angiogenesis. Hepatocyte growth factor (HGF) and its receptor, c-Met, are both overexpressed in the RA synovium. NK4 is an antagonist of HGF which has been shown to inhibit tumor growth, metastasis, and angiogenesis. In an experimental model of RA, NK4 gene therapy inhibited joint damage and inflammation in both preventative and therapeutic models. NK4 treatment therefore represents a possible therapeutic option in combating RA. BioMed Central 2013 2013-09-30 /pmc/articles/PMC3979028/ /pubmed/24074223 http://dx.doi.org/10.1186/ar4320 Text en Copyright © 2013 BioMed Central Ltd.
spellingShingle Editorial
Rabquer, Bradley J
Koch, Alisa E
NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
title NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
title_full NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
title_fullStr NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
title_full_unstemmed NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
title_short NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
title_sort nk4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979028/
https://www.ncbi.nlm.nih.gov/pubmed/24074223
http://dx.doi.org/10.1186/ar4320
work_keys_str_mv AT rabquerbradleyj nk4therapyanewapproachtotargetangiogenesisandinflammationinrheumatoidarthritis
AT kochalisae nk4therapyanewapproachtotargetangiogenesisandinflammationinrheumatoidarthritis

Ejemplares similares